JPRN-jRCTs021200019
Recruiting
N/A
Clinical evaluation on usefulness and safety of a new PET probe [18F]SMBT-1 in Alzheimer's disease and Progressive supranuclear palsy - PETSMBT1ADPSP
Tashiro Manabu0 sites24 target enrollmentAugust 25, 2020
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Alzheimer's disease (AD), Progressive Supranulcear Palsy (PSP)
- Sponsor
- Tashiro Manabu
- Enrollment
- 24
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Alzheimer's disease (AD) group
- •(1\) Informed consent by the participant or by the substitue (native Japanese)
- •(2\) Ages: 60 to 85 years old
- •(3\) Alzheimer's disease (AD), Progressive Supranulcear Palsy (PSP), Aged normal control (AN)
- •(4\) Those who were judged positive in \[11C]PiB PET for screening
- •(5\) Those who can tolerate relatively long PET examination (up to 2 hours)
- •Progressive Supranulcear Palsy (PSP) group
- •(1\) Informed consent by the participant or by the substitue (native Japanese)
- •(2\) Ages: 60 to 85 years old
- •(3\) Alzheimer's disease (AD), Progressive Supranulcear Palsy (PSP), Aged normal control (AN)
Exclusion Criteria
- •AD group and PSP group
- •(1\) Other neurological disorders (including cerebrovascular disorders), drug addicts, alcoholism, as well as severe cardiavascular diseases
- •(2\) Administration of irreversible MAO\-B inhibitors
- •(3\) Habitual smoking (including those who have smoked within 1 year)
- •(4\) Severe allergic reactions to drugs and foods
- •(5\) Psychiatric disorders, which may make the participation to this study difficult
- •(6\) Taboo conditions for MRI examinations (cardiac pacemaker, intracorpoporial metals, etc. to be checked with questionnaire in advance)
- •(7\) Systemic circulatory and metabolic disorders as well as organ dysfuctions, such as diabetes melitus, hypertension, endocrinological disorders, congestive heart failure, angina petoris, severe renal dysfunctions with Ccr\<30mL/min or under plasmapheresis)
- •(8\) Being diagnosed or treated for malignant diseases within 1 year
- •(9\) Any sociomedial conditions, which may make the participation to this study difficult
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
Phase 1
Evaluation of the safety and efficacy of the product in subjects experiencing hair lossCTRI/2018/03/012303Dabur Research Foundation
Recruiting
Phase 3
A clinical study to evaluate the efficacy and safety of the Vamana karma followed with two Rasayanas Takradhara and Rasaoushadi in treatment of psoriasis.Health Condition 1: null- Psoriasis (Kitibha)CTRI/2016/02/006631Central council for Research in Ayurvedic sciences CCRAS110
Completed
Phase 3
Evaluation of the Clinical Safety and Efficacy of Suprimun in Renal Transplant RecipientsComparative Interventional Treatment for reduceing the renal transplant rejection.kidney transplant rejectionIRCT2013012612274N1Vice-Chancellor for Research, Shahid Beheshti University of Medical Sciences100
Completed
Phase 3
Evaluation of the Clinical Safety and Efficacy of Suprimun in Renal Transplant RecipientsComparative Interventional Treatment for reduceing the renal transplant rejection.kidney transplant rejectionIRCT2014072118548N1Research Deputy of Kermanshah University Of Medical Sciences60
Completed
N/A
Clinical evaluation of the efficacy and safety of Hochuekkito for fatigue in patients with myeloproliferative neoplasmsmyeloproliferative neoplasmsJPRN-UMIN000031519Department of Hematology, Juntendo University School of Medicine110